Protecting Our Pharmaceutical Supply Chain from China Act of 2020

Fact Sheet API

Bill Number

HR 6482

Introduced

Apr 10, 2020

Latest Action

Referred to the Subcommittee on Oversight and Investigations.

Sponsor

Cosponsors

Topics

Asia Business expenses China Drug safety, medical device, and laboratory regulation Government information and archives Health Health care costs and insurance Health programs administration and funding Health technology, devices, supplies Income tax deductions Manufacturing Military medicine Military procurement, research, weapons development Prescription drugs Public contracts and procurement Trade restrictions Veterans' medical care

Full Text

View Full Bill Text

Votes

Summary

Protecting Our Pharmaceutical Supply Chain from China Act of 2020

This bill requires the federal government to maintain a registry of certain foreign-sourced drugs, prohibits federal health care programs from purchasing drugs containing Chinese ingredients, requires drugs to be labeled for country of origin, and offers domestic manufacturing facility tax incentives.

Actions

Jul 13, 2020

Referred to the Subcommittee on Oversight and Investigations.
Apr 10, 2020

Referred to the Subcommittee on Health.
Apr 10, 2020

Referred to the Committee on Energy and Commerce, and in addition to the Committees on Ways and Means, Armed Services, and Veterans' Affairs, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Apr 10, 2020

Introduced in House

Amendments

Related Bills